Chinese Acute Ischemic Stroke Treatment Outcome Registry

Ischemic Stroke Clinical Trial

— CASTOR  

Official title:

Chinese Acute Ischemic Stroke Treatment Outcome Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02470624
• Other study ID #: Neurology-stroke
• Status: Recruiting
• Phase: N/A
• First received: June 10, 2015
• Last updated: October 22, 2015
• Start date: May 2015
• Est. completion date: March 2017

Study information

• Verified date: October 2015
• Source: Peking University First Hospital
• Contact: Yining Huang, MD
• Phone: +86(10)83572857
• Email: ynhuang[@]sina.com
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is a multi-center registry study. The investigators will include 10,000 patients with confirmed acute ischemic stroke in China. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens.

Description:

Stroke is a common disease in China. Compared to western countries, there are many treatment regimens used in clinical practice in China. But their treatment effects are not well validated. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. age =18 yesrs

2. confirmed diagnosis of an ischemic stroke

3. admission within 1 week after onset of stroke or within treatment time window for patients of thrombolysis treatment

4. signed informed consent

Exclusion Criteria:

1. with intracerebral hemorrhage

2. with severe morbid (estimated survival duration less than 3 months)

3. could not provide follow-up information

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Other:
• treatment following current guideline

Locations

Country	Name	City	State
China	Peking University First Hospital	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Peking University First Hospital	Techpool Bio-Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	death or severe disability		90 days	Yes